Skip to main content
SpringerLink
Log in

Preclinical antitumor activity of batracylin (NSC 320846)

  • Preclinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Batracylin (NSC 320846, BAY H 2049), given ip on days 2 and 9 at a dose of 400 mg/kg, inhibited tumor growth completely in 80–100% of mice with early-stage colon adenocarcinoma 38. Therapeutic efficacy against this subcutaneously implanted tumor was retained upon oral administration of Batracylin although, compared to ip treatment, larger doses were required. Batracylin also caused regression of advanced (400 mg) colon 38 tumors. Only modest activity was observed for this compound against P388 leukemia, but P388 sublines with acquired resistance to either adriamycin or cisplatin demonstrated collateral sensitivity. Batracylin currently is undergoing toxicological evaluation by NCI prior to clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Goldin A, Schepartz SA, Venditti JM, Devita Jr VT: Historical development and current strategy of the National Cancer Institute drug development program. In: DeVita VT, Busch H (eds) Methods in Cancer Research, XVI. New York Academic Press, 1979, pp 165–245

  2. Goldin A, Venditti JM: The new NCI screen and its implications for clinical evaluations. In: Carter SK, Sakurai Y (eds) Recent Results in Cancer Research, 70. Springer-Verlag, 1980, pp 5–20

  3. Venditti JM: Preclinical drug development: rationale and methods. Semin Oncol 8: 349–361, 1981

    Google Scholar 

  4. Venditti JM: Wesley RA, Plowman J: Current NCI preclinical antitumor screening in vivo: Results of tumor panel screening, 1976–1982, and future directions. In: Garattini S, Goldin A, Hawking F (eds) Advance in Pharmacology and Chemotherapy, 20. Academic Press, Orlando FL, 1984, pp 1–20

    Google Scholar 

  5. Driscoll JS: The preclinical new drug research program of the National Cancer Institute. Cancer Treat Rep 68: 63–76, 1984

    Google Scholar 

  6. Boyd MR: National Cancer Institute drug discovery and development. In: Frei EJ, Freireich EJ (eds) Accomplishments in Oncology Vol.1 No.1, Cancer therapy: where do we go from here? Philadelphia JB Lippincott, 1986, pp 68–76

    Google Scholar 

  7. Corbett TH, Griswold Jr DP, Robert BJ, Peckham JC, Schabel Jr FM: Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 40: 2660–2680, 1977

    Google Scholar 

  8. Geran RI, Greenberg NH, Macdonald MM, Schumacher AM, Abbott BJ: Protocols for screening chemical agents and natural products against animal tumors and other biological systems (third edition). Cancer Chemother Rep (Part 3) 3: 1–103, 1972

    Google Scholar 

  9. Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute: In vivo cancer models 1976–1982. NIH Publication No. 84-2635, 1984

  10. Schabel Jr FM, Skipper HE, Trader MW, Laster Jr WR, Griswold Jr DP, Corbett TH: Establishment of cross-resistance profiles for new agents. Cancer Treat Rep 67: 905–922, 1983 (Table corrections: 68: 453–459, 1984)

    Google Scholar 

  11. Schabel Jr FM, Griswold Jr DP, Laster Jr WR, Corbett TH, Lloyd HH: Quantitative evaluation of anticancer agent activity in experimental animals. Pharmac Ther 1: 411–435, 1977

    Google Scholar 

  12. Shoemaker R, Wolpert-DeFilippes M, Plowman J, Abbott B, Venditti J, Trader M, Griswold D, Gerlach J, Ling V: Pleotropic resistance and drug development. In: Hall TC (ed) Progress in Clinical and Biological Research Vol. 223, Cancer Drug Resistance. Alan R Liss, Inc NY, 1986, pp 143–149

    Google Scholar 

  13. Plowman J, Narayanan VL, Dykes D, Szarvasi E, Briet P, Yoder OC, Paull KD: Flavone acetic acid: a novel agent with preclinical activity against colon adenocarcinoma 38 in mice. Cancer Treat Rep 70: 631–635, 1986

    Google Scholar 

  14. O'Dwyer PJ, Shoemaker D, Zaharko DS, Grieshaber C, Plowman J, Corbett T, Valeriote F, King SA, Cradock J, Hoth DF, Leyland-Jones B: Flavone acetic acid (LM 975, NSC 347512): A novel antitumor agent. Cancer Chemother Pharmacol 19: 6–10, 1987

    Google Scholar 

  15. Trader MW, Harrison Jr SD, Laster Jr WR, Griswold Jr DP: Cross-resistance and collateral sensitivity of drug-resistant P388 and L1210 leukemias to flavone acetic acid (FAA, NSC 347512) in vivo (Abstr). Proc Amer Assoc Cancer Res 28: 312, 1987

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, 20892, Bethesda, Maryland, USA

    Jacqueline Plowman, Kenneth D. Paull & V. L. Narayanan

  2. Institute Jules-Bordet, Brussels, Belgium

    Ghanem Atassi

  3. Southern Research Institute, 35255, Birmingham, Alabama, USA

    Steadman D. Harrison Jr. & Donald J. Dykes

  4. Bayer AG, 5090, Leverkusen, Germany FR

    Hans J. Kabbe

  5. Liaison Office, National Cancer Institute, Brussels, Belgium

    Omar C. Yoder

Authors
  1. Jacqueline Plowman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth D. Paull
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ghanem Atassi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Steadman D. Harrison Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Donald J. Dykes
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hans J. Kabbe
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. V. L. Narayanan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Omar C. Yoder
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Plowman, J., Paull, K.D., Atassi, G. et al. Preclinical antitumor activity of batracylin (NSC 320846). Invest New Drugs 6, 147–153 (1988). https://doi.org/10.1007/BF00175391

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00175391

Key words

Search

Navigation